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Summary We describe the results of treatment with 2'-deoxycoformycin (DCF) in 68 patients with post-
thymic (mature) T-cell malignancies. These included: prolymphocytic leukaemia (T-PLL), 31, HTLV-I + adult
T-cell leukaemia/lymphoma (ATLL), 20, cutaneous T-cell lymphoma (CTCL), comprising mycosis fungoides
and Sezary syndrome, 13, and large granular lymphocytic leukaemia, four. Two-thirds of patients were
refractory to previous therapy, which included four drug combinations. DCF was given intravenously at
4 mg m 2 weekly for the first 4 weeks and then every 2 weeks until maximal response. Toxicity was very low
with only one death resulting from prolonged neutropenia. Overall response rates, partial (PR) and complete
(CR), were 38%, with variations according to diagnosis. Best responses, 54%, were seen in CTCL but limited
to Sezary patients, one CR, six PR, whilst none of the mycosis fungoides responded. Responses in T-PLL were
recorded in 48% including three CR (of 8-12 months' duration unmaintained) and 12 PR. Fifteen per cent of
responses were seen in ATLL. The only ATLL responders - two CR, one PR - were those patients who
received combination chemotherapy prior to DCF, with reduction of tumour bulk but short of PR. When
results were analysed according to membrane phenotypes it was apparent that responses were seen mainly in
cases with CD4 +, CD8 - T cells - 22 of 47 (47%) - contrasting with only three of 19 (16%) with other
T-cell phenotypes. We conclude that DCF is a useful therapy for the treatment of T-cell leukaemias, in
particular Sezary syndrome and T-PLL, and should play a part in strategies to improve the natural history of
this group of lymphoid malignancies.
The mature T-cell leukaemias are an heterogeneous group of
disorders representing clonal proliferations of mature (post-
thymic) TdT and CDla negative immunocompetent lym-
phoid cells. At least four diseases can be recognised on
the basis of their clinical, morphological and immunological
features (Matutes & Catovsky, 1991): T-prolymphocytic leu-
kaemia (T-PLL), HTLV-I + adult T-cell leukaemia/lym-
phoma (ATLL), Sezary syndrome (SS) and large granular
lymphocyte (LGL) leukaemia.
LGL leukaemia often follows a relatively benign course
and most patients do not require active treatment. In con-
trast, T-PLL and ATLL usually have an aggressive course,
respond poorly to conventional chemotherapy and are assoc-
iated with poor survival (median 6 months). Until recently,
there has been a disappointing lack of innovative therapy for
these disorders.
Deoxycoformycin (DCF) is a potent inhibitor ofadenosine
deaminase, a key enzyme in the purine degradation pathway.
DCF has been shown to be selectively toxic to lymphocytes.
The exact mechanism of action is unknown but appears to
correlate with the accumulation of deoxyadenosine triphos-
phate (Mitchell et al., 1983). A variety of effects may be
involved and these have been reviewed elsewhere (Mitchell et
al., 1983; Begleiter et al., 1987; Lamballe et al., 1989; Ho et
al., 1988).
In early clinical trials in the 1970s, in which DCF was used
to treat relapsed and resistant cases of thymic derived (TdT
positive) T-lymphoblastic leukaemia, the high doses used
caused severe and unpredictable toxicity (Smyth et al., 1986).
More recent trials have defined safe and effective low dose
treatment schedules of the mature leukaemias (O'Dwyer et
al., 1988).
We describe here the response to DCF in a series of
patients with well characterised T-cell leukaemias. The aim of
our study is to define more precisely the spectrum of thera-
peutic activity of DCF in these diseases.
Patients and methods
2' deoxycoformycin (DCF; Pentostatin) was used to treat 68
patients with mature T-cell leukaemias and lymphomas. The
drug was supplied by the National Cancer Institute (USA)
for use with a protocol designed for these conditions. The
patients included 31 T-PLL, 20 ATLL, 13 with cutaneous
T-cell lymphoma (CTCL), including seven with Sezary synd-
rome and six with mycosis fungoides, and four LGL leu-
kaemia. The median age was 54 years with a range of 20-81
years. Fifty-nine per cent of the patients had received prior
systemic treatment with alkylating agents (chlorambucil) or
combination chemotherapy (e.g. CHOP, M-BACOD) and
were refractory to these agents. One third of them were
newly diagnosed and received DCF as first line therapy.
The diagnosis was based on cell morphology and immuno-
logical markers of blood, bone marrow, lymph node and/or
other biopsy material (Matutes & Catovsky, 1991).
DCF was administered by intravenous bolus injection at a
dose of 4mgm2 weekly for 4 weeks and then fortnightly
until optimal response was achieved and then stopped. The
dose was increased to 5mgm2 weekly in some responding
patients when the response was deemed suboptimal and there
was no toxicity. Criteria for response were as follows: com-
plete response (CR) consisted of the normalisation of the
blood counts, regression of the organomegaly and/or skin
lesions and significant reduction of bone marrow infiltration
without visible residual disease by conventional markers but
without resorting to immunophenotypic or genotypic clonal
markers; partial response (PR) when there was a 50% reduc-
tion of the above parameters. Both CR and PR were requir-
ed to be sustained for 3 months or longer. No response (NR)
was defined as less than 50% improvement or responses of
less than 3 months' duration.
Results
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The results are summarised in Table I. The overall response
rate (PR + CR) was 38%, ranging from 15% in ATLL to
54% in CTCL. The median duration of response was at least
6 months in all groups.
T-PLL
Out of 31 patients with T-PLL, three achieved a complete
response (CR) and 12 a partial response (PR) lasting up to
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Table I Treatment of mature T-cell leukaemias with deoxycofor-
mycin
Response
Number of CR PR CR + Duration (mths)
Disease patients (no) (no) PR% Median (Range)
T-PLL 31 3 12 48% 6 (3-12)
ATLL 20 2 1 15% 6 (2-36)
CTCLa 13 la 6a 54% 9 (5-66)
LGL leukaemia 4 1 0 25% 18
Total 68 7 19 38%
aSeven Sezary syndrome and six mycosis fungoides; all responders
had Sezary syndrome.
12 months. Fifteen patients received DCF as first line ther-
apy and these included two of the three CRs. However, there
were no differences in response rate (CR + PR) between
previously treated (7/16) and untreated (8/15) patients. One
patient achieved a rapid CR (Figure 1) which was sustained
off treatment for 10 months when recurrence of the disease
occurred and there was no subsequent response to DCF.
This patient is still alive on alternative therapy. The duration
of response in the other two complete responders was 8 and
12 months, respectively. One of them was retreated with
DCF with minor improvement and died 6 months later, and
the other died shortly after relapsing with progressive disease.
Among the 16 cases defined as non-responders, there were
five with a 4 to 10-fold reduction of the WBC but without
improvement in the organomegaly. There were no major
clinical or laboratory differences between responders and
non-responders except that responses were twice as frequent
in patients with the CD4 + CD8 - phenotype (Table II). The
median survival in the patients who responded with PR and
Cr to DCF was more than twice (16 months) that of the
non-responders (10 months). As yet this fails to show a
statistically significant difference in survival.
ATLL
The results of treatment in this group of patients have been
poor with only two complete and one partial response (Table
I). One patient died from an opportunistic infection whilst
still in CR 7 months from diagnosis and has been reported
elsewhere (Mattock et al., 1986). The other complete remitter
remained well for 36 months after completing treatment and
then relapsed with a cervical mass and leukaemia picture
(Figure 2); this patient did not respond a second time to
DCF. All three responders had been previously treated with
anthracycline-containing combination regimens (CHOP, M-
BACOD and PACE-BOM) shortly before receiving DCF
Table II Relationship between response and immunophenotype in
mature T-cell leukaemias treated with deoxycoformycin
CD4 + CD8 - Otherphenotype&
Disease No. Response" No. Response
T-PLLC 19 58% 11 27%
ATLL 17 18% 3 0
CTCL 9 78% 3 0
LGL leukaemia 2 50% 2 0
Total 47 47% 19 16%
The difference between the two groups was statistically significant
(P<0.05).aCD4 _, CD8 +; CD4 +, CD8 +;CD4-, CD8 bCR +
PR. cOne T-PLL and a CTCL were not tested for CD4/CD8.
and had achieved a reduction in disease 'bulk' as a result but
which was short of PR. At the start of treatment these three
patients had WBC<20 x 1091-, normal or only slightly
elevated serum calcium levels, and minor lymphadenopathy
or splenomegaly. In contrast, the 17 patients who failed
to respond to DCF had florid disease with one or more of
the following features: WBC> 50 x I091`, hypercalcaemia,
marked lymphadenopathy and splenomegaly.
CTCL
In this group of 13 patients there were one complete and six
partial responses and these included all the cases of Sezary
syndrome (Table I). Eleven of these patients had received
systemic chemotherapy and/or topical treatment prior to
DCF, without significant improvement. The single complete
responder, with extensive disease including lung and stomach
involvement and circulating small Sezary cells, had been
resistant to several courses of combination chemotherapy
with CHOP; she required 12 injections of DCF to achieve
CR. Currently, she is clinically well with minor evidence of
skin dermatitis, controlled with local steroids, and a few
circulating Sezary cells, 6 years after completing treatment
with DCF. All the partial responders experienced a dramatic
improvement of the skin lesions with marked symptomatic
improvement as well as a marked reduction in circulating
Sezary cells. None of the six patients with mycosis fungoides
responded to therapy.
LGL leukaemia
The only patient in this group with CR had the phenotype
CD4 +, CD8 -, CDllb +, unusual for this type of this
disease. After 18 months he relapsed and was retreated with
further benefit on two occasions before eventually dying of
progressive disease more than 4 years from the first treat-
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Figure 1 Haematological chart of the response of a patient with T-PLL.
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Figure 2 Haematological chart of a patient with ATLL treated with DCF.
ment. Two of the three non-responders had the typical
CD4 -, CD8 + cells seen in LGL leukaemia and in a third
the cells were CD4 +, CD8 -.
Table II shows the response rate in the different types
of mature T-cell leukaemia according to the membrane
immunophenotype of the malignant cells. Patients whose
cells have a CD4 + CD8 - phenotype respond significantly
better than those with other phenotypes.
Two T-PLL patients with CD4 + CD8 + cells and one
with CD4 - CD8 + achieved a partial response; all the
remaining responders, including the three in CR, were
CD4 + CD8 -. Overall, three times as many patients with a
CD4 + CD8 - phenotype responded to DCF, with the
proportions being higher in CTCL (78%), compared with
those with other phenotypes.
Toxicity
DCF has been well tolerated in the low doses administered
with one third of patients experiencing mild to moderate
nausea following the injections. There has been no docu-
mented renal or hepatic toxicity except in one patient who
developed cholestatic jaundice, reversible with the cessation
of DCF. Pancytopenias were rarely documented and only in
one patient prolonged neutropenia resulted in a fatal infec-
tion. In all other cases fatalities occurred later and were due
to progressive disease without any direct relationship to
DCF.
Discussion
We have previously suggested (Dearden et al., 1987), in a
small group of patients with a mature T-cell leukaemia, that
response to DCF appears to correlate with membrane pheno-
type. This finding has been confirmed by the results reported
here in a significantly larger group of patients. The higher
response rate seen in cases with a CD4 + CD8 - phenotype
is particularly noticeable in patients with T-PLL (58%) and
-CTCL (75%). The reasons for this difference are unknown
but it has been suggested that they reflect the differential
effect of DCF on normal CD4 and CD8 subsets.
T-PLL is a disease which has been shown to respond
poorly to conventional chemotherapy, with only a few
reported cases benefiting from CHOP or mediastinal irradia-
tion (Catovsky & Foa, 1990). Based on our findings, we
believe that in cases of CD4 + T-PLL DCF should be
regarded as the first choice of therapy. Karyotypic abnor-
malities, particularly inversion 14 and trisomy 8q (Brito-
Babapulle & Catovsky, 1991), are common in this disease
(76% of cases) and it was interesting that the cells from one
of the three complete responders were karyotypically normal.
Patients with Sezary syndrome are frequently managed in
the early stages with topical therapies (PUVA, electron
beam) and may not be referred for systemic chemotherapy
until an advanced stage in the disease when the overall
outlook is poor. The good results we have seen in this disease
indicate that DCF is an agent which warrants consideration
in early treatment for control of both skin and blood mani-
festations. Results in the treatment ofmycosis fungoides have
been much less promising with none of the six patients
treated with DCF showing any useful response.
Current therapies for ATLL have produced disappointing
results and DCF has been no exception. In cases where the
disease is aggressive with a rapidly expanding tumour burden
it would appear that DCF alone is insufficient to control
disease progression. Our results here suggest that responses
(CR or PR) were obtained in patients in whom DCF was
given following a bulk reduction with combination chemo-
therapy. In the future, studies using such an approach or
with regimens combining DCF with CHOP or etoposide may
be worth exploring. New therapies are clearly needed for this
rapidly fatal T-cell malignancy.
This study shows that the precise haematopathological
diagnosis of the type ofT-cell leukaemia and of the immuno-
phenotype has helped define better the disease in which DCF
may be useful, namely T-PLL and Sezary syndrome and,
overall, cases with a CD4 +, CD8 - phenotype. Even so, it
appears that the natural history of these aggressive T-cell
disorders may not be altered radically by the use of DCF
alone. In ATLL there is a suggestion that reduction of
disease bulk may facilitate the subsequent DCF response. We
are now exploring this approach in a new series of ATLL
patients, including some in which a CR or PR is obtained
first with combination chemotherapy and DCF as mainten-
ance to prevent the usual rapid relapses.
This study was supported by Trust Funds from The Royal Marsden
Hospital. We are grateful to all our many colleagues who referred
patients for treatment and for their assistance in supplying inform-
ation on patients under their care.
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